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METHODOLOGY Open Access
Design, planning and implementation
lessons learnt from a surgical multi-centre
randomised controlled trial
Katie Biggs1* , Daniel Hind1, Mike Bradburn1, Lizzie Swaby1 and Steve Brown2
Abstract
Background: Increasingly, pragmatic randomised controlled trials are being used to evaluate surgical interventions,
although they present particular difficulties in regards to recruitment and retention.
Methods: Procedures and processes related to implementation of a multi-centre pragmatic surgical randomised
controlled trial are discussed. In this surgical trial, forecasting of consent rates based on similar trials and micro-
costing of study activities with research partners were undertaken and a video was produced targeting recruiting
staff with the aim of aiding recruitment. The baseline assessments were reviewed to ensure the timing did not
impact on the outcome. Attrition due to procedure waiting time was monitored and data were triangulated for the
primary outcome to ensure adequate follow-up data.
Results: Forecasting and costing ensured that the recruitment window was of adequate length and adequate
resource was available for study procedures at multiple clinics in each hospital. Recruiting staff found the
recruitment video useful. The comparison of patient-reported data collected prior to randomisation and prior to
treatment provided confidence in the baseline data. Knowledge of participant dropout due to delays in treatment
meant we were able to increase the recruitment target in a timely fashion, and along with the triangulation of data
sources, this ensured adequate follow-up of randomised participants.
Conclusions: This paper provides a range of evidence-based and experience-based approaches which, collectively,
resulted in meeting our study objectives and from which lessons may be transferable.
Trial registration: ISRCTN, ISRCTN41394716. Registered on 10 May 2012.
UKCRN Study ID: 12486.
Background
Randomised controlled trials (RCTs) are becoming more
widely used to assess surgical interventions despite histor-
ical resistance [1–3]. However, a review across surgical spe-
cialities showed over 20% (81/395) of trials are prematurely
discontinued [4], with poor recruitment being the principal
reason (36/81); these discontinued trials recruited 15,626
participants. The discontinuation of trials results in consid-
erable wasted investment and at best a less precise answer
to the research question [5–7]. Poor recruitment and reten-
tion can lead to withdrawal of funding to complete the trial,
which has financial and ethical implications [5, 6, 8].
McCulloch and colleagues [1] identified different classes
of surgical trials with different levels of risk in terms of suc-
cessful project completion: type 1 trials compare medical
management in surgery; type 2 compare surgical techniques;
and type 3 compare surgical and non-surgical treatments.
Type 3 trials are particularly prone to a lack of clinician and
patient equipoise [1]. Recruitment to trials with treatments
of differing intensity are often poor [1, 9], with randomized-
to-screened ratios of 1:16 documented [10].
The most common patient-reported reasons for non-
entry into surgical RCTs are treatment preference or dis-
like of randomisation [11, 12] and, where treatments are
markedly different, there is increased likelihood of pa-
tients or clinicians declaring a preference. In addition,
recruiting clinicians often struggle to explain concepts
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such as randomisation and equipoise [13–15] and with
the amount and clarity of information provided during
the consent process [8]. There have been several articles
looking at strategies to improve recruitment and reten-
tion in trials [5, 8, 13, 16–20] and evidence for successful
interventions is limited. Qualitative work alongside sur-
gical trials can identify particular issues around recruit-
ment and can train staff to address the absence of
equipoise and other issues [13].
The time waited from consent to surgery is a common
reason for attrition [21, 22] and type 3 trials may lead to
a greater difference in waiting times between treatment
groups than types 1 or 2. With increasing waiting times
a problem for some health systems [23], this should be a
consideration in surgical trial design. Baseline measures
such as health-related quality of life (HRQoL) often
change over time, meaning long waiting times between
consent and surgery are a potential source of bias. If
baseline measures are taken on the day of surgery there
is a possibility that the measures could be affected by
the knowledge of the treatment allocation [24]. The clin-
ically intuitive timing for follow-up measures is a time-
point relative to the day of surgery, whereas the
scientifically desirable timing is a timepoint relative to
the day of randomisation, although there is some evi-
dence that this makes little difference to the reported
outcomes [25].
Costing the resource required to deliver RCTs is an
important factor in their success. Published workload
models for organisations tend to use accrual data, acuity,
or a points scale to estimate the research nurses and/or
clinical trial administrator/co-ordinator resource needed
to implement an RCT [6–11]. There is no consensus on
which model best evaluates workload in clinical research
infrastructure [12]. Systems that reimburse research in-
frastructure based on accrual data focus on the target
accrual compared to the number of whole-time equiva-
lents (WTEs), often without accounting for screen fail-
ures, query resolution, long-term follow up, participant
attrition, or the complexity of the research protocol.
They are criticised for over-simplicity and implicated in
staff burnout and poor quality standards [12, 13]. This
paper presents lessons from the Haemorrhoidal artery
ligation (HAL) versus rubber band ligation (RBL) for
haemorrhoids (HubBLe) trial [26–28], a type 3, multi-
centre, surgical RCT, to support the implementation of
future studies.
Methods
Summary of trial design and procedures
The aim of the HubBLe trial [26–28] was to establish
the clinical effectiveness and cost effectiveness of HAL
compared with RBL in the treatment of people with
symptomatic second or third degree haemorrhoids. Both
treatments are recommended for the treatment of hae-
morrhoids [29–32]. The trial was a pragmatic, multi-
centre, parallel group RCT involving 18 National Health
Service (NHS) hospitals in England and Scotland. After
consent, participants were individually randomised to
HAL or RBL in equal proportions at all centres using a
web-based randomisation system. Participants were
followed up at 1 day, 7 days and 21 days, 6 weeks, and 12
months post-procedure. Full details of the trial methods
can be found elsewhere [26–28]; here, we focus on
methods aimed at improving participant recruitment
and retention to achieve a valid data set.
Methods adopted to meet the recruitment target
Recruitment procedures
Eligibility criteria were broad in order to assure a large
pool of patients from which to recruit, whilst ensuring
patients were suitable for both procedures. HubBLe can
be considered a type 3 trial in which medical manage-
ment is compared with a surgical intervention [1, 9]:
HAL was a procedure undertaken in theatre under gen-
eral anaesthetic; RBL is a less intensive intervention, typ-
ically undertaken as an outpatient procedure, and is
often delivered by non-surgeons. A key reason for
under-recruitment in RCTs is over-optimism at the trial
planning stage regarding how many people who are of-
fered participation in the trial will consent and random-
ise [33–36].
In particular investigators often do not forecast based
on a “reference class” of consent rates observed in previ-
ous similar trials [34, 37]. Prospect theory predicts that
we are over-optimistic in our judgements, because we
are overconfident and unaware or ignorant of existing
data on similar projects (the “reference class”) [38–40].
For HubBLe, we made the following evidence-based as-
sumptions about the recruitment activity based on a ref-
erence class of previous similar studies:
1. Many patients had to be screened for one patient to
consent
For type 3 surgical trials, conversion rates rarely ex-
ceed 1 patient consented for every 5 screened and rates
as low as one randomised for every 16 screened [9, 10].
We therefore anticipated that 12 patients will decline
randomisation for each one who consents, a screening-
to-randomisation ratio of 13:1.
2. Time spent per patient screened
Every patient screened would cost a research nurse 3 h
in terms of liaison with the clinical team to ensure po-
tentially eligible candidates were flagged; posting infor-
mation about the study in advance of screening visits;
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time taken to get to screening visits in clinics; screening,
information giving and discussion of equipoise issues;
and consent and randomisation where required. For
every patient recruited we requested costs for 38.5 h re-
cruitment work. Assuming the conversion rate of 1 pa-
tient randomised in every 13 screened, recruiting 39
patients at a centre would require 1500 h (roughly 0.7
WTE over 1 year at each centre).
3. Coverage and rationalisation
There were an estimated two eligible patients available
per clinic. With an estimate of four surgeons involved at
every centre and an estimate of four clinics per centre
per week, we recognised the challenge for recruiting re-
search nurses to be available at all clinics with poten-
tially eligible patients (coverage). Given the anticipated
screening-randomised-ratio, it was imperative that as
many potentially eligible patients were screened as pos-
sible. Research nurses worked with clinical teams to
corral potentially eligible patients into particular clinics,
especially where multiple surgeons share a waiting room.
The research nurse could then use their time more effi-
ciently with a view to minimising the number of un-
screened patients (rationalisation).
Attribution and reimbursement of costs
The UK Government Department of Health’s system for
attributing costs in NHS research and development
(R&D) [41] means that resource for recruitment activity
cannot be costed into grant applications. A case for sup-
plementary funding for work relating to recruitment,
“services support costs”, has to be made to a National
Institute for Health Research (NIHR) Local Research
Network (LRN) lead in the chief investigator’s locality.
Once agreed, LRNs in other regions are expected to
match the funding. The system has been the subject of
criticism by researchers and delays associated with
agreeing the allocation of costs have been documented
[42–46]. To avoid such delays, we entered into discus-
sion with the LRN, which began prior to the start of the
study. The breakdown of research nurse costs for Hub-
BLe are presented in Table 1; we ensured that the re-
search nurse resource accounted for screen failures,
participant attrition, data collection, data entry, query
resolution, and the complexity of the research protocol.
Recruitment video
In addition to ensuring sufficient recruitment capacity
for the trial, the team developed a recruitment video
[47] based on the ProtecT trial team’s work on the
explanation of randomisation and equipoise [13]. We
interviewed the local ProtecT trial team, two research
nurses and a consultant involved in recruitment,
about their recruitment experiences and narrated the
film to highlight the general principles of equipoise
and randomisation and how this specifically related to
HubBLe. A recent systematic review of training inter-
ventions for trial recruiters [8] identified six trials
[48–53] that had employed a video as part of a face-
to-face workshop for that purpose, but there do not
seem to be any training programmes solely using vid-
eos to aid recruiters. This was seen to be a low-cost
method that could be referred to by recruiters as
many times as they wished.
Monitoring of waiting times
The duration between randomisation and treatment was
monitored in the trial as we knew that there can be signifi-
cant issues with waiting times for non-urgent surgeries,
and that this could affect dropout rates and the intention-
to-treat analysis. Whilst RBL is a simple procedure, which
is often done on the day of randomisation, HAL is more
intensive, is performed under general anaesthetic and re-
quires a theatre slot to be booked. These conditions cre-
ated the potential for differential participant attrition, a
potential source of bias in our analysis [54, 55]. During the
trial one of the centres stopped completing non-urgent
surgery, which included our procedures. This has been
shown to be a continuing issue for the NHS with one
Clinical Commissioning Group (CCG) suspending non-
urgent surgery to make financial savings prior to the end
of the financial year in 2017 [56, 57]. Due to the long wait-
ing times, for the HAL procedure in particular, and the
cancellation of non-urgent procedures at one site, the
dropout rate prior to the procedure was higher than antic-
ipated. To account for this observed attrition the recruit-
ment target was increased to 370, during the study, in
Table 1 Costing of research nurse time per centre
Activity Cost
Year 1 (recruitment and follow-up):
Research nurse to screen and
recruit patients (recruitment
activity).
Research costs (research acitivty):
0.3 whole time equivalent (WTE) of
a research nurse for the 12 month
recruitment period for research
activity.
Undertake data collection for
the research, data entry,
monitoring and meeting
attendance (research activity).
Service support costs (recruitment
activity): 0.7 WTE - We looked the
LRNs to make up a full time post
(based on our assumption about
recruitment activity).
Year 2 (follow-up only):
12 month follow-up (a half hour
telephone interview plus data
entry) and closeout visit, plus
support for any monitoring and
audit activity required.
Research costs: £300 per
participant recruited
Biggs et al. Trials          (2019) 20:620 Page 3 of 12
order to achieve the sample of 350 treated, followed up
and analysed participants.
Changes in baseline health state post-randomisation, pre-
surgery
Three months into recruitment the baseline data collection
was changed to the day of procedure, rather than at ran-
domisation. This was because there was substantial
between-site variation in surgical wait times, and a differ-
ence in wait times for the two treatments, meaning that
scores for change in patient-reported outcome at follow up
may have reflected time periods substantially greater than
intended, especially in the HAL arm. The risk of bias intro-
duced by anchoring follow up to the time of surgery, rather
than the point of randomisation, is theoretical and not sup-
ported by empirical evidence [25].
Six months after this change a Data Management and
Ethics Committee (DMEC) member suggested that
patient-reported outcomes can be affected by the know-
ledge of their allocation. Since baseline data collection
took place on the day of surgery, most patients already
knew their allocation by this point; the concern was that
perceived pain and HRQoL may differ between the
groups due to expectation bias at this time [24], even
though no procedure had yet taken place. The trial stat-
istician reported that the early data did indeed support
this hypothesis, in particular with higher self-reported
symptoms in the HAL arm. As a result of this, we added
a questionnaire to be completed before randomisation as
well as at baseline on the day of surgery if the two were
more than 1 week apart.
Methods to ensure a valid primary outcome data set
Three sources of primary data collection
Sometimes, in assessing an outcome, using only one
data source may be unreliable and data source tri-
angulation is necessary [58]. Our primary objective
was to compare patient-reported symptom recurrence
at 12 months following the procedure. Recurrence was
defined using a simple dichotomous outcome derived
from a previously published systematic review [59].
Patients were asked “At the moment, do you feel your
symptoms are: cured or improved compared with be-
fore starting treatment; or unchanged or worse com-
pared with before starting treatment.” We also asked
patients whether (and which) procedures they had
undergone for their haemorrhoids, further to trial
treatment, since symptoms may only have resolved as
a result of further intervention, and supplemented
this with treatments as determined from their hospital
notes and general practitioner (GP) in order to min-
imise attrition and recall bias. Finally, we reviewed
adverse events and hospitalisations to identify
participants that had ongoing symptoms consistent
with persistent or recurrent haemorrhoids (e.g. per-
sistent bleeding) that had not been treated.
Results
Recruitment
Recruitment took place from 9 September 2012 to 6
May 2014, with follow up completed on 28 August 2015.
The target and actual recruitment, including the increase
in the recruitment target is shown in Fig. 1. There were
372 participants randomly assigned to receive RBL or
HAL; 187 patients were allocated to receive RBL and
185 were allocated to receive HAL. Two of these partici-
pants (both allocated to RBL) were removed from the
trial completely as they were ineligible at the time of
consent, meaning a total of 370 participants were en-
tered into the trial. An important observation is that less
than one quarter of the sites (study sites 1, 2, 6, and 9)
account for two thirds of the participants (251/372),
while half of sites contributed one sixth of randomised
participants.
Our early funding discussions with sites reduced delays
in site set-up prior to the start of recruitment, and the lead
site even started 1 month earlier than anticipated. Where
sites agreed to our proposal, a full-time research nurse
was dedicated to HubBLe during the recruitment period.
Sites that exceeded their target recruitment (1, 2, 6 and 9)
had a named research nurse responsible for the trial, as
did sites 4, 7, and 8, though they did not recruit to target.
An informal observation was that at sites where research
nurses had less time to work on the trial, recruitment and
the non-recruited data collection were generally poorer.
Of the 969 patients screened, 198 were not eligible (in-
cluding the 2 patients that were withdrawn); the majority
of these patients were not approached as clinical note
review identified the exclusion criteria. The approximate
randomised-to-screened ratio in the trial was 5:13; we
therefore needed to formally screen (approximately) 13
people for every 5 randomised. This may underestimate
the number of individuals screened, as the recording of
data from non-recruited patients can be poor in clinical
trials as the focus is on recruited participants.
Of the 401 eligible screened patients that were not re-
cruited, 109 of these were not approached and 292 were
invited to the trial but refused to consent; reasons for
non-consent are shown in Table 2. Most patients who re-
fused to consent did not want to be randomised due to
their preference for a particular treatment (251/401, 62%).
Video feedback
Although we did not assess the impact of the video on re-
cruitment in any formal or structured sense, recruiting
staff fed back that thinking about equipoise was very help-
ful, and that they found it easier to describe the two
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treatments after watching the video. Particular key points
that were highlighted as helpful from the video were that
it expressed the uncertainty of the effectiveness of each
treatment; gave a similar amount of time discussing each
treatment arm and avoid loaded statements that may
communicate an unconscious bias for one treatment over
another; and it provided the opportunity to check the pa-
tient’s understanding as you go.
Withdrawals and waiting times
Overall, 35 participants withdrew from the trial, with 24
withdrawing from the HAL group and 11 from the RBL
group; reasons for withdrawal are provided in Table 3.
Only 3 participants withdrew after receiving treatment
and these were all in the RBL group: of the 32 participants
that did not receive the procedure, 24 participants were in
the HAL group compared with 8 in the RBL group.
Figure 2 shows the time between randomisation and treat-
ment for participants at each site, excluding site 17, which
randomised no participants. The median waiting times were
longer for HAL (62 days) than that for RBL (0 days) as RBL
was often done on the day of randomisation at the sites.
Figure 3 shows that withdrawal prior to treatment in the
HAL group occurred after waiting longer than participants
who withdrew in the RBL group. Withdrawal of consent
often occurred when contacting patients to book them in
for treatment or discuss their waiting time. The majority of
participants who withdrew prior to treatment did so after
Table 2 Reasons for non-enrolment to the trial
Reason Frequency
Not eligible 198
Patient not approached 109
Clinical decision 41
Patient did not attend appointment/uncontactable 26
Unknown 42
Patient approached 292
Patient preference 251
Patient preference for RBL 128
Patient preference for HAL 70
Patient did not want any intervention or treatment 39
Patient preference for other surgery 5
Patient preference for immediate treatment 3
Patient preference related to general anaesthetic 6
Patient unsure or declined (no further reason given) 29
Other reason 12
Total 599
Adapted with permission from Brown et al. 2016 [27]. HAL haemorrhoidal
artery ligation, RBL rubber band ligation
Bold text represents the higher-level reason for non-recruitment, with the
detailed breakdown provided by the non-bold text
Bold text represents the higher-level reason for non-recruitment, with the
detailed breakdown provided by the non-bold text
Fig. 1 Participant recruitment graph. Reproduced with permission from Brown et al. 2016 [27]
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waiting more than a month for the procedure (29/32). Site 5
had particular problems with their waiting times, eventually
stopping non-urgent surgical procedures: eight participants
did not receive the HAL procedure, and four did not receive
the RBL procedure due to withdrawal of consent, loss to fol-
low up, or receiving treatment elsewhere.
Changes in symptoms between randomisation and
procedure
Due to the differences in waiting time between ran-
domisation and procedure (Fig. 2), data from the
baseline assessment were reviewed to see if expect-
ation bias or clinical deterioration was evident. The
early accumulating data indicated that this was pos-
sible. Figure 4 depicts the pre-treatment means for
self-reported symptoms and incontinence against time
during the recruitment period and, as can be seen,
the mean incontinence scores were initially higher in
the surgery arm than in the RBL arm; a similar but
less pronounced pattern was also noted for symp-
toms. To address this, a pre-randomisation question-
naire was introduced, with a second questionnaire
given on the day of the procedure only where more
than a week had elapsed between randomisation and
the procedure. The group means converged by the
end of recruitment, suggesting the initial differences
were artefacts of relatively small sample sizes.
The differences in means between pre-randomisa-
tion and pre-treatment (baseline) measures (Table 4)
were not significant in any of the patient-reported
measures, which reassured us that there was no
systematic change due to expectation bias or clinical
deterioration. Nevertheless, there were some consider-
able differences between the two measures on an in-
dividual level. To put this into context, the 95%
reference intervals for change between randomisation
and procedure included 0.5 standard deviations, a
magnitude comparable to or exceeding the minimally
clinically important difference in many RCTs. More-
over, the variability of the change (the ratio of vari-
ances, Table 4) was greater in the HAL arm for two
of the four questionnaires (Vaizey faecal incontinence
Fig. 2 Time to procedure by site and treatment arm (days). HAL, haemorrhoidal artery ligation; RBL, rubber band ligation
Table 3 Reason for withdrawal (reasons for withdrawal from
treatment are indicated under “Prior to treatment”)
Reason for withdrawal HAL
N = 24
RBL
N = 11
Prior to treatment
Found to be ineligible
after randomisation
0 2
Participant withdrew consent 15 3
Lost to follow up
prior to procedure
6 2
Symptoms resolved/
treated elsewhere
2 1
Ineligible at time
of procedure
1 0
After treatment
Participant withdrew
consent
0 3
Reproduced with permission from Brown et al. 2016 [27]. HAL haemorrhoidal
artery ligation, RBL rubber band ligation
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and the Euroqol - 5 dimensions - 5 levels (EQ-5D-
5L) questionnaires), suggesting these were either
sensitive to temporal trends and/or lacked test-retest
validity - although on average these changes cancelled
each other out in terms of the mean change.
Primary outcome
Our primary outcome was recurrence at 1 year post-
treatment. This included a patient-reported outcome
measure supplemented by a case note review of further
treatment and haemorrhoid-related events.
Fig. 3 Time to withdrawal (prior to treatment) by site and treatment arm (days). Figure includes only those sites experiencing participant attrition
prior to treatment. HAL, haemorrhoidal artery ligation; RBL, rubber band ligation
Fig. 4 Baseline patient-reported haemorrhoid symptom score and incontinence as taken on day of procedure. HAL, haemorrhoidal artery ligation;
RBL, rubber band ligation
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Figure 5 and Table 5 show that data were collected
from all three sources (patient, consultant, and GP) on
183 participants and the best method for data collection
was from the hospital notes (consultant questionnaire),
with 337 (96% of the sample of 350) of these completed.
If we had only relied on the patient-reported outcome
we would have had outcome data on 255 participants
(73% of the sample of 350). Figure 5 shows that recur-
rence was reported by 71 participants at 1 year but that
83 participants had received further treatment as re-
ported in the GP or consultant questionnaire. In total
135 participants were found to have had a recurrence,
which would have been underestimated had only one of
these sources been used for the primary outcome.
Consolidated standards of reporting trials (CONSORT)
diagram
The complete trial information in relation to recruitment
and data collection is provided in the CONSORT diagram in
Fig. 6. Overall there was a good rate of recruitment, with 372
out of the 969 screened recruited and a low rate of attrition,
with 337 (90.6%) contributing to the primary outcome. As
our original target was 350, our attrition rate was 3.7%, less
than the 5% used for our sample size calculation [26, 27].
Discussion
Statement of findings
The HubBLe trial is a relatively rare example of a surgi-
cal trial that recruited to target and maintained adequate
participant follow up. The HubBLe team reduced the
risk of project failure by addressing four key areas. We
increased the chances of recruiting to target with broad
eligibility criteria as suggested elsewhere [5, 33–36];
forecasting recruitment rates based on previous studies
[34, 37, 60]; accounting for screen failures in resourcing
recruitment activity; and highlighting the issue of equi-
poise in the training of recruitment staff as proposed by
Donovan and colleagues [13–15]. However, as expected
for treatments of differing intensity [11], patient prefer-
ence for treatment was still a barrier to recruitment. In
addition, we reduced the risk of delays to recruitment, as
recommended [42–46], by having early discussions with
sites to secure funding for recruitment activity. As wait-
ing times have been shown to be a barrier to treatment
[21, 61], we anticipated differences in the time from ran-
domisation to treatment in each arm [54], reducing the
risk of bias due to differential attrition. We avoided vari-
ation in length of follow up between arms by collecting
baseline data on the day of surgery in addition to ran-
domisation. We then compared the data to check for the
Table 4 Agreement between self-completed measures of symptoms, incontinence, EQ-5D-5 L, and pain pre-randomisation and pre-
treatment (baseline)
Measure Mean change (95% agreement limits) Difference in
mean change
Ratio of
variances
HAL RBL
Haemorrhoid symptom score 0.0 (−3.0, 3.0) 0.1 (−3.0, 3.1) −0.1 (p = 0.823) 0. 96 (p = 0.864)
EQ-5D-5L −0.01 (− 0.13, 0.11) −0.00 (− 0.12, 0.11) −0.01 (p = 0.508) 1.11 (p = 0.691)
Vaizey Faecal incontinence score −0.1 (−5.6, 5.3) 0.4 (−2.7, 3.5) −0.5 (p = 0.231) 3.14 (p < 0.001)
VAS pain 0.2 (− 3.8, 4.2) −0.0 (− 2.5, 2.4) 0.2 (p = 0.479) 2.63 (p < 0.001)
Reproduced with permission from Brown et al. 2016 [27]. HAL haemorrhoidal artery ligation, RBL rubber band ligation, EQ-5D-5L Euroqol - 5 dimensions - 5 levels
questionnaire, VAS visual analogue scale
Fig. 5 Source of primary outcome data collection. GP,
general practitioner
Table 5 Data sources for recurrence at one year
RBL (N = 176) HAL (N = 161)
Recurrence at
one year (total)
87 (49%) 48 (30%)
Self-reported recurrencea 37 (29%b) 34 (29%b)
Data from GP and
consultant questionnairesa
60 (35%) 23 (14%)
Adapted with permission from Brown et al. 2016 [27]. HAL haemorrhoidal
artery ligation, RBL rubber band ligation, GP general practitioner
aIndividuals may contribute data to both measures of recurrence
bDenominator is number of patients returning questionnaire
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influence of expectation bias on self-report measures, as
suggested by Schulz [24], but found no systematic differ-
ences between the two timepoints. In “Primary outcome”
we reduced the risk of unreliable data by triangulating
across three sources [58].
Strengths and limitations
This paper shows how a trial can use a battery of
evidence-based methods and the collected experience of a
clinical trials unit [62] to achieve study objectives. We
were not resourced to conduct qualitative research along-
side the trial to understand and address recruitment is-
sues, as is now best practice [19, 63] and our approach
was somewhat ad hoc, with systematic evaluation of the
strategies not conducted. For instance, formal feedback on
the recruitment training video, which was produced with-
out any funding, was not elicited to improve future efforts
and screening data may have been incomplete, as is com-
mon in RCTs [64], and time spent screening patients was
not monitored so we cannot determine if our costing of
recruitment activity was appropriate.
Meaning and application of findings
The data in this paper, such as those on consent rates and
attrition prior to treatment, can be added to the reference
class for surgical trials and used in future forecasting. Data
Fig. 6 Participant flow diagram. Reproduced with permission from Brown et al. 2016 [27]. HAL, haemorrhoidal artery ligation; RBL,
rubber band ligation, GP, general practitioner
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showing the imbalance in recruitment between trial sites
are important: difference in site capability is frequently ob-
served and has implications for trial planning [65–69], es-
pecially in allowing over-recruitment in site contracts to
compensate for less able sites.
The paper highlights issues around waiting times for
surgery in the UK [25, 70–73] and how this can differ
between arms in type 3 trials [9], which should be
accounted for in the sample size estimation and when
deciding on the timing of data collection. Consideration
needs to be given to whether baseline data should be
collected at randomisation or on the day of treatment
[25]; though our data show there is little difference be-
tween timepoints. Decisions on whether follow-up data
should be anchored to randomisation or to the trial
treatment also need to be made: if HubBLe had an-
chored follow up to randomization rather than to trial
treatment, the time between treatment and follow up
would have been greater in the RBL group due to the
longer waiting times for HAL, which in turn could have
affected the primary outcome of recurrence.
Unanswered questions and future research
It may not be possible to repeat the comparatively
generous allocation of service support costs to this
trial in the UK due to the subsequent introduction of
the Department of Health’s new costing template (the
Activity Capture and Attribution Tool, or ACAT) and
the UK Clinical Research Facility Network Intensity
Tool to cost research nurse activity. Our experience
on more recent trials is that these two tools may con-
siderably underestimate the research nurse time ne-
cessary to undertake essential research procedures,
threatening the success of the recruitment effort and
the integrity of research data. Published workload
models estimating staff resource for RCTs [74–79]
are often criticised for over-simplicity, and their use
can lead to staff burnout and poor implementation
[80–82]. The rise of surgical trainee networks in the
UK as a force in recruitment may go some way to
compensating for the pressures on costs in public
sector research, where trainees can be incentivised
and co-ordinated to recruit and follow up study par-
ticipants [83].
Stronger evidence for recruitment and retention strat-
egies in RCTs is required to improve trial efficiency and
meet trial objectives. Trial Forge [84] is an initiative set
up to address the lack of evidence in trial decision-
making, which will go some way to evaluate recruitment
and retention strategies that can be used across RCTs.
The use of studies within a trial (SWATs) to find evi-
dence for implementation of RCTs is becoming more
commonplace and could be used to assess some of the
strategies presented in this paper [85–87].
Conclusions
Recruitment to and retention in trials comparing surgi-
cal interventions of different intensity is challenging but
achievable. This paper provides a range of evidence-
based and experience-based approaches, which collect-
ively resulted in meeting our study objectives and from
which lessons may be transferable.
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